BOSTON SCIENTIFIC: Sales miss consensus

(AOF) – Boston Scientific has released disappointing forecasts. The American giant of medical equipment expects for its fourth quarter ended at the end of December on a turnover of 2.71 billion dollars, down 6.8%. The FactSet consensus is for 2.86 billion.


Excellent prospects for the sector

According to Moody’s, the turnover of the sector should increase by 4 to 6% in 2021, against 2 to 4% initially forecast.

The top five vaccine manufacturers (Pfizer-BioNTech, Moderna, AstraZeneca, Novavax and Johnson & Johnson) should benefit greatly from this growth, even if there are uncertainties about production capacities. Treatment manufacturers (Gilead, Eli Lilly and Regeneron in particular) should not be left out.

Alongside the opportunities there are also threats, one of which is potential price reductions, especially in the United States, the world’s largest market. The rise of biosimilars (generics of biological drugs) should also help pull prices down.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.